1,2,3,5,6-Penta-O-propanoyl-D-glucofuranose - CAS 307531-77-7
Category:
Carbohydrates
Product Name:
1,2,3,5,6-Penta-O-propanoyl-D-glucofuranose
CAS Number:
307531-77-7
Molecular Weight:
460.47
Molecular Formula:
C21H32O11
COA:
Inquire
MSDS:
Inquire
Structure:
Monosaccharides
Chemical Structure
CAS 307531-77-7 1,2,3,5,6-Penta-O-propanoyl-D-glucofuranose

Related Monosaccharides Products


Reference Reading


1.Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: A multi-national cohort.
Rodger MA1, Scarvelis D2, Kahn SR3, Wells PS2, Anderson DA4, Chagnon I5, Le Gal G2, Gandara E2, Solymoss S6, Sabri E2, Kovacs MJ7. Thromb Res. 2016 Mar 29. pii: S0049-3848(16)30087-1. doi: 10.1016/j.thromres.2016.03.028. [Epub ahead of print]
BACKGROUND: Choosing short-term (3-6 months) or indefinite anticoagulation after a first unprovoked venous thromboembolic event (VTE) is a common and difficult clinical decision. The long-term absolute risk of recurrent VTE after a first unprovoked VTE, in all patients and sub-groups, is not well established, hindering decision making.
2.Use of PET tracers for parathyroid localization: a systematic review and meta-analysis.
Kluijfhout WP1,2, Pasternak JD3, Drake FT4, Beninato T4, Gosnell JE4, Shen WT4, Duh QY4, Allen IE5, Vriens MR6, de Keizer B7, Pampaloni MH8, Suh I4. Langenbecks Arch Surg. 2016 Apr 16. [Epub ahead of print]
PURPOSE: The great spatial and temporal resolution of positron emission tomography might provide the answer for patients with primary hyperparathyroidism (pHPT) and non-localized parathyroid glands. We performed a systematic review of the evidence regarding all investigated tracers.
3.Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan.
Koh K1, Ogawa C2,3, Okamoto Y4, Kudo K5,6, Inagaki J7, Morimoto T8, Mizukami H9, Ecstein-Fraisse E9, Kikuta A10. Int J Hematol. 2016 Apr 16. [Epub ahead of print]
A phase 1 study was conducted to evaluate the safety, pharmacokinetics (PK), efficacy and pharmacogenetic characteristics of clofarabine in seven Japanese pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL). Patients in Cohort 1 received clofarabine 30 mg/m2/day for 5 days, followed by 52 mg/m2/day for 5 days in subsequent cycles. Cohort 2 patients were consistently treated with 52 mg/m2/day for 5 days. No more than six cycles were performed. Every patient had at least one ≥Grade 3 adverse event (AE). AEs (≥Grade 3) related to clofarabine were anaemia, neutropenia, febrile neutropenia, thrombocytopenia, alanine aminotransferase increased, aspartate aminotransferase increased, haemoglobin decreased, and platelet (PLT) count decreased. C max and AUC of clofarabine increased in a dose-dependent fashion, but its elimination half-life (T 1/2) did not appear to be dependent on dose or duration of treatment. Clofarabine at 52 mg/m2/day shows similarly tolerable safety and PK profiles compared to those in previous studies.
4.Neurotic personality and pseudo-cardiac symptoms in a day hospital patients diagnosed at pretreatment between 2004 and 2014.
Sobański JA1, Popiołek L1, Klasa K2, Rutkowski K1, Dembińska E1, Mielimąka M1, Cyranka K1, Müldner-Nieckowski Ł1. Psychiatr Pol. 2016;50(1):213-246. doi: 10.12740/PP/60818.
OBJECTIVES: Assessment of associations between occurrence of pseudocardiac symptoms in patients qualified for psychotherapy, with intensity and picture of their neurotic personality disorder.